Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414388 · ClinicalTrials.gov registry record · Phase 1
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
A Phase 1 study, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00414388 is a Phase 1 study that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 22 participants.
The verdict
NCT00414388, a Phase 1 study, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of combining Sorafenib and chemotherapy (mitoxantrone or docetaxel) in patients with AIPC.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414388
The ClinicalTrials.gov registry entry for NCT00414388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00414388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414388 about?
NCT00414388 is a clinical study titled "Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer". The primary objective of this study is to evaluate the safety of combining Sorafenib and chemotherapy (mitoxantrone or docetaxel) in patients with AIPC.
What is the current status of trial NCT00414388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-12. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00414388?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00414388?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.